Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520839 | 0.85 | ALDH1A1 (0.47) | MAPTLMNAALDH1A1HPGDGAA | |
| SCHEMBL7220858 | 0.82 | SGMS2 (0.48) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL16955161 | 0.81 | MAPT (0.55) | MAPTLMNAALDH1A1RECQLMEN1 | |
| SCHEMBL31432402 | 0.79 | TRPV4 (0.54) | MAPTLMNAALDH1A1RECQLMEN1 | |
| SCHEMBL15173367 | 0.79 | ALDH1A1 (0.54) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL2967916 | 0.78 | CALM1 (0.45) | MAPTLMNAALDH1A1MEN1MAPK1 | |
| SCHEMBL1829547 | 0.77 | MAPT (0.49) | MAPTALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL19122665 | 0.77 | MAPT (0.51) | MAPTLMNAALDH1A1RECQLMEN1 | |
| SCHEMBL18159198 | 0.77 | SMN1; SMN2 (0.54) | LMNAALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5068198 | 0.76 | LMNA (0.51) | MAPTLMNAALDH1A1RECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| EP-1737826-A1 | ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005075438-A1 | ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES | TANABE SEIYAKU CO., LTD. (JP) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005075438-A1 | ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES | TANABE SEIYAKU CO., LTD. (JP) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | ITGB4, ITGA4, ICAM1 | MAPT 2408/4885LMNA 1529/4885ALDH1A1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.